Zobrazeno 1 - 10 of 817 pro vyhledávání: '"Aaron Kesselheim"'
2
Why Eyes? Cautionary Tales from Law’s Blindfolded Justice1All rights reserved. November 2015. Thanks are due to Aaron Kesselheim for inviting us to write for this volume; to the Yale Law Library, Fred Shapiro, and Michael Widener; to Allison Tait, who joined us in much of this research, to Reva Siegel for many discussions of constitutional theory; to Ruth Weisberg, Peter Goodrich, and Valérie Hayaert for exchanges about iconography, to Benjamin Woodring and Marianna Mao for able research assistance, and to Bonnie Posick for expert editorial oversight. This chapter is related to our book, from which we draw several of the images provided there. See Judith Resnik and Dennis Curtis, Representing Justice: Invention, Controversy and Rights in City-States and Democratic Courtrooms, New Haven: Yale University Press, 2011. In addition, parts of this discussion are derived from our essay, Epistemological Doubt and Visual Puzzles of Sight, Knowledge, and Judgment: Reflections on Clear-Sighted and Blindfolded Justices. In: P. Goodrich & V. Hayaert (Eds.), Genealogies of Legal Vision. Routledge: 2015
Autor: Judith Resnik, Dennis E. Curtis
For thousands of years, in many parts of the world, sight was valorized, and obscured vision equated with disability, vice, and caprice. More recently, blindfolds have become emblematic of impartial judging, freed from bias. This chapter analyzes the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::79975c9c237b6dfbd7ba9a4215d2a774
https://doi.org/10.1016/b978-0-12-802460-7.00015-2
Zobrazit plný text záznamu
3
Patent 'Evergreening' of Medicine–Device Combination Products: A Global Perspective
Autor: Reed Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam Houston, Aaron Kesselheim, Jason Nickerson, Warren Kaplan
Publikováno v: Healthcare Policy | Politiques de Santé. 18:14-26
Patenting medicine-delivery devices (inhalers and pens) is controversial when it extends market protections beyond that of the underlying therapeutic agent. We evaluated how common device patenting is, internationally.Using a product sample (n = 88)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::524bc440f9a093cca6b61e7ac35d85f1
https://doi.org/10.12927/hcpol.2022.26973
Zobrazit plný text záznamu
4
Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis
Autor: Doni Bloomfield, Elvira D’Andrea, Sarosh Nagar, Aaron Kesselheim
Publikováno v: JAMA oncology. 8(4)
Biologics account for almost half of US drug spending but may be subject to competitive pricing pressures by US Food and Drug Administration-approved biosimilars. The extent of the preapproval clinical testing that is needed and how these biosimilars
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e343df644a8aca2e3f16350ad57144f
https://pubmed.ncbi.nlm.nih.gov/35113156
Zobrazit plný text záznamu
6
Alternatives to the quality-adjusted life year: How well do they address common criticisms?
Autor: Leah Rand, G.J. Melendez-Torres, Aaron Kesselheim
Publikováno v: Health services researchREFERENCES.
To analyze whether other outcome measures used in health technology assessment (HTA) address the criticisms of quality-adjusted life years (QALYs).HTA methods guidance from 11 US comparator countries (the G10 and Australia) and six value frameworks f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16b7f8b171ec179dc84a88332f32e746
https://pubmed.ncbi.nlm.nih.gov/36537647
Zobrazit plný text záznamu
9
Making the Case for Accelerated Withdrawal of Aducanumab
Autor: Peter Whitehouse, Sam Gandy, Vikas Saini, Daniel R. George, Eric B. Larson, G. Caleb Alexander, Jerry Avorn, Shannon Brownlee, Cameron Camp, Howard Chertkow, Adriane Fugh-Berman, Rob Howard, Aaron Kesselheim, Kenneth M. Langa, George Perry, Edo Richard, Lon Schneider
Publikováno v: Journal of Alzheimer's Disease, 87, 1003-1007
Journal of Alzheimer's Disease, 87, 3, pp. 1003-1007
Journal of Alzheimer's Disease, 87(3), 1003-1007. IOS Press
The controversial approval in June 2021 by the Food and Drug Administration (FDA) of aducanumab (marketed as Aduhelm), Biogen’s monoclonal antibody for patients with Alzheimer’s disease, raises significant concerns for the dementia field and drug
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9f3751407fc056dcf533e597660054e
http://hdl.handle.net/2066/251120
Zobrazit plný text záznamu
10
Akademický článek
Analysis of risk evaluation and mitigation strategies for teratogenic drugs: Variation in primary and secondary prevention measures.
Autor: Brown, Beatrice L.1 (AUTHOR), Kesselheim, Aaron S.1 (AUTHOR), Sarpatwari, Ameet1 (AUTHOR) asarpatwari@bwh.harvard.edu
Publikováno v: PLoS Medicine. 3/6/2023, Vol. 19 Issue 3, p1-9. 9p. 3 Charts.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje